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OBJECTIVES: To describe the statins prescriptive patterns in primary or secondary          
prevention patients, to quantify treatment adherence and persistence and to produce 
data useful to administrators for better health care planning. METHODS: Five phar- 
macoutilization observational retrospective studies were conducted in ﬁve italian Local 
Healthare Units, using the same methodology and statistical plan. Two databases 
(Pharmacy Claims and Hospital Discharges) were queried to select subjects with at 
least one statin prescription during the study period or an hospitalization for ischemic 
cerebro-cardiovascular causes. Record linkage was carried on using personal tax code 
as primary key (replaced with an anonymous code to ensure compliance with privacy 
rules). Subjects were classiﬁed in primary or secondary prevention (absence or presence 
of cerebro-cardiovascular events and/or at least two antidiabetics prescriptions) and 
in occasional or not-occasional users (time between the ﬁrst and last prescription was 
a28 days or 28 days). A statin tablet was assumed as treatment unit. Adherence was 
quantiﬁed as MPR (Medication Possetion Ratio): ratio of tablets dispensed during 
the follow-up and the follow-up duration. Persistence was estimated using “Life 
Table” and Kaplan-Meier methods. A multiple linear regression model was built to 
describe adherence predictors. RESULTS: Demographic characteristics of the 5     
samples are essentially superimposable. Occasional users vary from 24% to 75%, 
mainly in younger classes, females and primary prevention. MPR ranges from 39% 
to 59% and seems better in males and secondary prevention. After 6 months of treat-
ment likelihood to stop therapy varies from 50% to 70% and it is lower in males and 
secondary prevention. Sex, age, type of cardiovascular prevention, follow-up duration 
and statin switch absence seem the major adherence predictors. CONCLUSIONS: 
Adherence and persistence levels with statin therapy are far from optimal values, 
resulting in failure to maximize therapy effectiveness and health care resources 
investment.
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QUANTIFICATION METHODS OF ITALIAN PREVALENT POPULATION 
SUFFERING FROM ATRIAL FIBRILLATION USING PUBLISHED 
EPIDEMIOLOGICAL DATA
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OBJECTIVES: Atrial ﬁbrillation (AF) is the most common arrythmia whose preva-
lence increases signiﬁcantly with age. Few epidemiological studies give prevalence 
stratiﬁed by age classes. In order to evaluate disease burden it is crucial to estimate 
AF prevalence by speciﬁc age and quantify subjects with AF over Italian population. 
METHODS: Published epidemiological studies in which prevalence by age is reported 
were searched. Italian studies were privileged and International literature considered 
only if quoted in Italian guidelines. For each selected study prevalence was estimated 
by best ﬁtting a logistic function for increasing age classes. Age-speciﬁc prevalence 
was then calculated for each year of age and related to Italian population age distribu-
tion to estimate the number of AF cases. RESULTS: Quoted in AF Italian Guidelines, 
CASTEL, Framingham and ATRIA studies give prevalence stratiﬁed by increasing age 
classes. For each study the logistic function gave the best ﬁt, and provided very similar 
ﬁtting parameters. Reported prevalence for Framingham study are 0.5% for 50–59 
years, 1.8% for 60–69 years, 4.8% for 70–79 years, 8.8% for 80–89 years while those 
estimated by the ﬁtting are 0.8%, 2.1%, 4.6% and 8,6% respectively. Projecting the 
estimated prevalence over the entire Italian population (58.6 millions), 761,438 AF 
cases (CL95% 540,022–1.058.308) are estimated to be distributed within age ranges as          
follows: 28,718 in 50 years, 62,652 in 50–59 years, 137,256 in 60–69 years, 244,149 
in 70–79 years, 214,003 in 80–89 years and 74,660 in q90 years. With the same 
approach very similar projections are obtained with ATRIA study (763,458 CL95%: 
479,101–1,194,111), while for CASTEL study higher estimates (831,285 CL95%: 
374,849–1,718,830) result. CONCLUSIONS: This quantiﬁcation method allows an 
estimate of AF prevalent cases for the entire population, for speciﬁc ages or age classes 
and may represent the basis for further estimates.
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OBJECTIVES: TRITON-TIMI 38 demonstrated reduced thrombotic events associated 
with increased bleeding in patients taking prasugrel compared with clopidogrel. Treat-
ment compliance has previously been reported for the overall trial population but not 
for the lower bleeding risk (LBR) group of patients characterized by age 75 years, 
weight q60 kg, and no prior TIA/stroke. The objective of this analysis was to compare 
persistence, discontinuation rates, and reasons for discontinuation among LBR 
patients receiving prasugrel versus clopidogrel. METHODS: A total of 10,727 of 
13,608 patients from TRITON-TIMI 38 were identiﬁed to be in the LBR population 
(prasugrel: N  5390, clopidogrel: N  5337). Patients were followed for up to 15 
months. Persistence was measured as the time from randomization to the ﬁrst gap of 
14 days in which the patient was not known to be taking study drug and comparison 
made between treatment arms using a Cox proportional hazards model and control-
ling for demographics and medical history. RESULTS: Similar persistence levels were 
observed for prasugrel-treated patients and clopidogrel-treated patients (327 vs. 329 
days, p  0.856). Sensitivity analyses using 7-day and 30-day gaps conﬁrmed this 
ﬁnding. Among the studied population, 15.8% prasugrel patients and 15.7% clopi-
dogrel patients (p  0.923) prematurely discontinued their study medication. Among 
patients who permanently discontinued their medication, the most common reason 
recorded was “patient decision” (52.4% for prasugrel, 54.0% for clopidogrel, p  
0.517). Discontinuation due to hemorrhagic adverse events was more common among 
prasugrel than clopidogrel patients (11.3% vs. 6.7%, respectively, p  0.001); discon-
tinuation due to non-hemorrhagic adverse events was not signiﬁcantly different 
between drugs (25.6% vs. 28.3%, respectively, p  0.219). CONCLUSIONS: Overall, 
similar persistence and discontinuation rates were observed for prasugrel and clopi-
dogrel for this LBR patient population. In both groups, patient decision was more 
likely to contribute to discontinuation than were adverse events.
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CONFORMATION OF BLEEDING QUANTITY MEASURED AFTER HEART 
OPERATIONS UNDER THE EFFECTS OF CERTAIN HARMFUL HABITS 
AND OPERATIVE DATA
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OBJECTIVES: Based on earlier studies it is known that certain harmful habits play 
an important role in the development of the cardiovascular diseases which inﬂuence 
development of complications and the successfulness of the rehabilitation after the 
operation. The aim of this study is to analyze whether the examined harmful habits 
and certain operative data inﬂuence the bleeding quantity after heart operation. 
METHODS: Retrospective analysis was made on the University of Pécs Cardiotherapy 
Clinic among patients went through heart operation (n  611) between January 1, 
2007 and December 31, 2007 in Hungary. Statistical tests: khí2 test, variance analysis 
(ANOVA), Pearson-Spearman correlation coefﬁcient examination was made. Data 
processing was done with SPSS 15.0 and MS Excel programs. RESULTS: Signiﬁcant 
difference was found between the total bleeding and the alcohol consumption habits 
(p  0.001). No connection was found with smoking habits (p  0.05). Direct propor-
tion was found between aorta clinch time (p  0.03), the time of heart engine (0.039) 
and the use of the red blood cells. CONCLUSIONS: Postoperative bleeding is inﬂu-
enced by many factors: antecedents of patients, perioperative medication, operative 
data, and surgical technique. Based on the result of studies certain harmful habits and 
other operative data inﬂuence the postoperative bleeding in patients went through 
open heart operation.
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PANDORA STUDY
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OBJECTIVES: Peripheral Arterial Disease (PAD) is a form of atherosclerotic disease          
conferring a cardiovascular (CV) risk equivalent to that of coronary heart disease. 
Despite its association with a high risk of CV events, PAD is potentially under-
 diagnosed. The primary objective of the current study was to assess the prevalence of 
asymptomatic PAD through measurement of Ankle-Brachial Index (ABI) in subjects 
at moderate CV risk. METHODS: PANDORA (NCT00689377) was a non-    
 interventional, cross-sectional, multi-centre study conducted in six European coun-
tries. The study required a single visit in which eligible and consenting subjects at 
moderate CV risk (males aged q45 or females aged q55 years, plus at least one addi-
tional risk factor, with no overt CV disease or diabetes mellitus) underwent ABI 
measurement. Investigators also completed a Subject Record Form with data relevant 
to patient demographics, vital signs, CV risk factors, lipid levels and current treatment. 
Moreover, both investigators and patients completed questionnaires regarding their 
opinions on CV diseases. We report here the results from Greece. RESULTS: A total 
of 840 subjects (789 evaluable) were enrolled by 120 ofﬁce-based physicians across           
Greece. Mean (o SD) age was 62.1 (9.1) years and mean BMI (         o SD) was 29.6 (4.3)    
kg/m2. A total of 61.2% were male and 47% were smokers. Hypertension was present 
in 73.5% of patients. Prevalence of asymptomatic PAD, deﬁned as ABI a 0.90, was 
28% (95% CI 24.88–31.14). In multivariate analysis, hypertension [Odds Ratio 
(OR) 2.48, 95% CI 1.58–3.89, p  0.0001], low HDL-C (OR 2.27, 95% CI 
1.55–3.32, p  0.0001) and divorced marital status (OR 2.63, 95% CI 1.14–6.07, 
p  0.023) were found to be strong determinants for PAD. CONCLUSIONS: Asymp-
tomatic PAD was highly prevalent in subjects with moderate CV risk treated by 
ofﬁce-based physicians in Greece. ABI measurement is a signiﬁcant tool in identifying 
subjects at higher risk who may require earlier and possibly more aggressive 
intervention.
